- Home
- GNRC vs ARWR Comparison
GNRC vs ARWR Comparison
Compare GNRC & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | ARWR |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 12.4B |
| IPO Year | 2009 | 2009 |
Fundamental Metrics
Financial Performance| Metric | GNRC | ARWR |
|---|---|---|
| Price | $206.30 | $67.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $211.75 | $83.40 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $4,209,147,000.00 | $16,142,321.00 |
| Revenue This Year | $17.36 | N/A |
| Revenue Next Year | $12.51 | N/A |
| P/E Ratio | $56.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $134.80 | $30.77 |
| 52 Week High | $296.44 | $95.49 |
Technical Indicators
Market Signals| Indicator | GNRC | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 25.28 |
| Support Level | $198.21 | $60.60 |
| Resistance Level | $211.98 | $71.83 |
| Average True Range (ATR) | 7.21 | 4.01 |
| MACD | 2.85 | -2.24 |
| Stochastic Oscillator | 52.78 | 10.13 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.